Form 4: Cassava Sciences Chief Medical Officer Granted Stock Options

James William Kupiec, Chief Medical Officer of Cassava Sciences, was granted stock options for 100,000 shares on September 6, 2024.

Summary

• James William Kupiec, the Chief Medical Officer of Cassava Sciences, was granted stock options to purchase 100,000 shares of Cassava Sciences common stock.
• The transaction occurred on September 6, 2024.
• The exercise price of the stock options is $26.91 per share.
• The options vest over two years, with 50% vesting one year after the grant date and the remaining 50% vesting two years after the grant date.
• The options expire on September 6, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine event, but it signals confidence in the executive and aligns interests with shareholders.

Positives

• The granting of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment and performance.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders. This grant is typical for a Chief Medical Officer role.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
• Companies like Biogen, Eli Lilly, and Pfizer also utilize stock options to incentivize their executives.
• The vesting schedule of 50% after one year and 50% after two years is fairly standard, aligning with typical industry practices for executive stock option grants.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns management's interests with the company's long-term success.
• The Chief Medical Officer is incentivized to improve the company's performance to increase the value of the stock options.

Key Dates